WELCOME to Stu's Views and MS News

Key-Note: Our live MS educational seminars average 65 people per educational program. SINCE our first program in February 2010, we have hosted more than 120 educational programs.

Register at our website (MS Views and News) to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in more than (90) Countries. Visit MS Views and News.org

WATCH OUR Multiple Sclerosis archived MS EDUCATIONAL VIDEOS by Topic. Click: www.youtube.com/msviewsandnews

Be Empowered with Beneficial MS Information

Scroll to view all the resources found on the left side of this blog. Use our 'search by topic' tool, when wanting to find specific information.

===================================================================

Friday, November 2, 2012

The Lancet criticizes Sanofi for cost of Lemtrada, withdrawal of Campath


PARIS (Reuters) - Medical journal The Lancet warned that Sanofi's experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators.
The journal, which published the encouraging results of two late-stage Lemtrada tests on Thursday, also criticized the drugmaker's decision to withdraw leukemia therapy Campath, the same drug given at a different dosage, depriving MS patients who had been using it off-label.
In an editorial accompanying the test results, The Lancet voiced concerns that Lemtrada would be priced higher than current MS drugs on the market and said the discontinuation of Campath may mean patients who had used it for MS would not be able to continue their treatment.
The injectable drug, chemically known as alemtuzumab, was sold until September 2012 under the name Campath as treatment for leukemia and given more frequently at a higher dosage.


Read more: http://medcitynews.com/2012/10/the-lancet-criticizes-sanofi-for-cost-of-lemtrada-withdrawal-of-campath/#ixzz2B6jj3dCc


..


If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left
 REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register
.

No comments: